{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344646","form_type":"8-K","ticker":"CDXS","cik":"0001200375","company_name":"CODEXIS, INC.","filed_at":"2026-08-11T20:11:09+00:00","discovered_at":"2026-08-11T20:12:00.387415+00:00","generated_at":"2026-08-11T20:12:18.329559+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Codexis Q2 revenue $14.9M, net loss $12.0M; reiterates FY guidance","bullets":["Q2 2026 revenue $14.9M vs $15.3M YoY; net loss $12.0M ($0.13/sh) vs $13.3M ($0.16/sh).","Product gross margin 73% vs 72% YoY; cash at June 30 was $54.9M.","Completed July equity raise of ~$25M net proceeds; proforma cash ~$80M.","Reiterated FY2026 revenue guidance of $72-76M; high 60% gross margin; cash runway through 2028.","TIDES US data showed ECO Synthesis stereoisomer control for siRNA; GMP facility permit application planned H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344646","json":"https://secwatch.observer/filing/0001193125-26-344646.json","markdown":"https://secwatch.observer/filing/0001193125-26-344646.md","text":"https://secwatch.observer/filing/0001193125-26-344646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1200375/000119312526344646/0001193125-26-344646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1200375/000119312526344646/d171403d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:12:18.329559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}